SEC Form 4	
------------	--

 \square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	ROVAL								
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

D

D

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Zhang Xiaoyan Michelle (Last) (First) C/O IKENA ONCOLOGY, INC.				uer Name and Tick na Oncology, te of Earliest Transa 0/2022	<u>Inc.</u> [IKN	Ă]		elationship of Reporting Person(s) to Issuer ck all applicable) Director 10% Owner Officer (give title Other (specif below) below) Chief Scientific Officer			
645 SUMMER STREET, SUITE 101 (Street) BOSTON MA (City) (State) (Zip)				4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Indi Line) X	,		
	Т	able I - Nor	n-Derivative	Securities Acq	uired	, Dis	posed of,	or Ber	neficially	Owned		
Date		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Ins					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V		Amount (A) or (D) Pri		Price	Transaction(s) (Instr. 3 and 4)		(1150.4)	
Common Stock 01/10		01/10/2022		М		36	A	\$2.1462	44,511	D		
Common Stock 01/10/2			01/10/2022		S ⁽¹⁾		36	D	\$12	44,475	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned	
(e.g., puts, calls, warrants, options, convertible securities)	

М

S⁽¹⁾

964

964

A

D

\$2.1462

\$<mark>12</mark>

45,439

44,475

L															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deriv Secu Acqu (A) o Dispo of (D (Insti	of Expiration D		xpiration Date Ionth/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$2.1462	01/10/2022		М			36	(2)	12/17/2028	Common Stock	36	\$0.00	25,437	D	
Stock Option (Right to Buy)	\$2.1462	01/11/2022		М			964	(2)	12/17/2028	Common Stock	964	\$0.00	24,473	D	

Explanation of Responses:

Common Stock

Common Stock

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2021.

01/11/2022

01/11/2022

2. 25% of the shares subject to this option vested and became exercisable on December 14, 2018, with the remainder vesting in 36 substantially equal monthly installments thereafter. **Remarks:**

> /s/ Douglas R. Carlson, as Attorney-in-Fact for Xiaoyan Michelle Zhang

01/12/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.